epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Colestid
    colestipol
  • remove Erivedge
    vismodegib
  • remove Estrostep Fe
    norethindrone/ ethinyl estradiol
  • remove Ortho Micronor
    norethindrone

multicheck MultiCheck Results - 4 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Estrostep Fe (norethindrone/ ethinyl estradiol) + Ortho Micronor (norethindrone)

Avoid/Use Alternative


norethindrone (contraceptive) + norethindrone (contraceptive)

avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

Monitor/Modify Tx

Smiley face Smiley face Colestid (colestipol) + Estrostep Fe (norethindrone/ ethinyl estradiol)

Monitor/Modify Tx


colestipol + ethinyl estradiol (contraceptive)

give oral contraceptive at least 1h before or 4h after each colestipol dose: combo may decr. ethinyl estradiol levels, contraceptive efficacy (absorption decreased/delayed)

colestipol + norethindrone (contraceptive)

give oral contraceptive at least 1h before or 4h after each colestipol dose: combo may decr. norethindrone levels, contraceptive efficacy (absorption decreased/delayed)

Smiley face Smiley face Colestid (colestipol) + Ortho Micronor (norethindrone)

Monitor/Modify Tx


colestipol + norethindrone (contraceptive)

give oral contraceptive at least 1h before or 4h after each colestipol dose: combo may decr. norethindrone levels, contraceptive efficacy (absorption decreased/delayed)

Additional Considerations

Smiley face Smiley face colestipol in Colestid

give oral drugs at least 1h before or 4h after colestipol; bile acid sequestrant may delay or decr. absorption of concomitant oral drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information